SS-31 Study Explained: Elamipretide SS-31 promotes recovery by preserving mitochondrial

Quick answer

SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹ The result belongs to the exact population, outcome, and design described in the source. For Filipino readers, that makes SS-31 an evidence question first and a separate product-verification question second. That order keeps the short answer useful without turning it into personal guidance or a sales promise. The sections below show how the finding, limitation, and product check fit together.

What did researchers actually examine?

Readers do not need a technical background to follow SS-31 study on Elamipretide promotes recovery by. They do need the study context in plain language and a clear explanation of the main limit.

Researchers found that the MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.²

The study design provides the frame: the MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.²

One caution belongs beside that result: this was the overall result for a genetically diverse population.²

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What was the clearest result?

The most useful conclusion about SS-31 study on Elamipretide promotes recovery by is the one another reader can retrace. The citation should lead back to the exact result described here.

The measured outcome was clear: a phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.³

The source places the result in this setting: the randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point.³

The practical limitation is this: this was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.³

What does the wider research add?

This is where the SS-31 study on Elamipretide promotes recovery by headline needs context. The study design explains what the result can carry and where the interpretation should stop.

The study reported that in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.⁴

The setting matters: the study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.⁴

The main limit is equally important: this is an animal study, and the result is for the combination, not elamipretide alone.⁴

Which limits belong beside the finding?

For Filipino readers, SS-31 study on Elamipretide promotes recovery by is clearest when the global research and the exact local record remain separate checks.

Researchers found that the MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.²

The study design provides the frame: the MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.²

One caution belongs beside that result: this was the overall result for a genetically diverse population.²

How does product identity fit the story?

Readers do not need a technical background to follow SS-31 study on Elamipretide promotes recovery by. They do need the study context in plain language and a clear explanation of the main limit.

The measured outcome was clear: SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹

The source places the result in this setting: the FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.¹

The practical limitation is this: this is a description of its mechanism of action from regulatory and laboratory sources.¹

The paper’s main result was that the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁵ That result does not erase its main limit: a portal record applies to the exact product or establishment named in that record.⁵

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers verify?

The most useful conclusion about SS-31 study on Elamipretide promotes recovery by is the one another reader can retrace. The citation should lead back to the exact result described here.

The study reported that in a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.⁶

The setting matters: the 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it.⁶

The main limit is equally important: this was an open-label study with a small number of participants, and all knew they were receiving the active drug.⁶

The central finding was specific: WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.⁷ The finding should stop here: appearance alone cannot authenticate a product or establish a research outcome.⁷

Bottom line

The clearest reading is that SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹

This is a description of its mechanism of action from regulatory and laboratory sources.¹ For Filipino readers, the research result and the exact local product record remain separate checks.

That approach keeps SS-31 informative without turning one study into personal advice, a universal promise, or proof about a catalog product.

For this SS-31 study on Elamipretide promotes recovery by question, the strongest conclusion is the one that keeps the cited outcome and its original setting together.

Frequently asked questions

What is the short answer about SS-31?

The cited source gives a focused answer: SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹ The conclusion stays tied to that study’s population, method, and measured outcome.

Does one positive result settle the whole topic?

No. This was an open-label study with a small number of participants, and all knew they were receiving the active drug.⁶ A useful result can remain narrow without being dismissed or promoted as a universal benefit.

Why does the study context matter?

The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.² Changing the population, comparison, formulation, or endpoint would change the question, so those details belong beside the finding.

What should Filipino readers verify?

SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹ Check the exact name and record shown by the official source instead of assuming that a familiar molecule name covers every listing.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In this SS-31 study on Elamipretide promotes recovery by guide, the cards are live catalog references for navigation. They do not prove study equivalence, turn research into a product claim, or suggest that the two items should be used together.⁸

Sources

Footnotes

1. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

2. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24. This was the overall result for a genetically diverse population. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

3. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.. The randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point. This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit. ↩ ↩² ↩³

4. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.. The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy. This is an animal study, and the result is for the combination, not elamipretide alone. ↩ ↩² ↩³

5. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩²

6. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩² ↩³ ↩⁴

7. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩²

8. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.; Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩